山东步长制药股份有限公司第五届 董事会第四十三次会议决议公告

Core Viewpoint - The company held its 43rd meeting of the 5th Board of Directors, where it approved two key proposals regarding equity transfer and participation in restructuring investment bidding [1][5]. Group 1: Equity Transfer Proposal - The company agreed to the transfer of 1% unpaid equity of its subsidiary, Shandong Buchang Guanyou Medical Equipment Co., Ltd., from shareholder Liu Anan to Zhu Binbin at a price of RMB 0, while waiving its right of first refusal [2][11]. - After the transfer, the company's ownership in Buchang Guanyou will remain at 90% [11][13]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations, and does not require shareholder approval [11][12]. Group 2: Restructuring Investment Bidding Proposal - The company plans to participate in the bidding for restructuring investor qualifications to expand its presence in the traditional Chinese medicine sector, aligning with its strategic vision of becoming "China's Johnson & Johnson" [5][18]. - Due to the uncertainties and commercial confidentiality involved in this transaction, specific details will be disclosed after the bidding process concludes [5][18]. - The proposal was also approved by the Board's Strategic and Investment Committee before being presented to the Board [3][6].